Xiaofang Chen

Abram Schonfeldt, Benjamin Maylor, Xiaofang Chen et al.

Introduction: Data from wearable devices collected in free-living settings, and labelled with physical activity behaviours compatible with health research, are essential for both validating existing wearable-based measurement approaches and developing novel machine learning approaches. One common way of obtaining these labels relies on laborious annotation of sequences of images captured by cameras worn by participants through the course of a day. Methods: We compare the performance of three vision language models and two discriminative models on two free-living validation studies with 161 and 111 participants, collected in Oxfordshire, United Kingdom and Sichuan, China, respectively, using the Autographer (OMG Life, defunct) wearable camera. Results: We found that the best open-source vision-language model (VLM) and fine-tuned discriminative model (DM) achieved comparable performance when predicting sedentary behaviour from single images on unseen participants in the Oxfordshire study; median F1-scores: VLM = 0.89 (0.84, 0.92), DM = 0.91 (0.86, 0.95). Performance declined for light (VLM = 0.60 (0.56,0.67), DM = 0.70 (0.63, 0.79)), and moderate-to-vigorous intensity physical activity (VLM = 0.66 (0.53, 0.85); DM = 0.72 (0.58, 0.84)). When applied to the external Sichuan study, performance fell across all intensity categories, with median Cohen's kappa-scores falling from 0.54 (0.49, 0.64) to 0.26 (0.15, 0.37) for the VLM, and from 0.67 (0.60, 0.74) to 0.19 (0.10, 0.30) for the DM. Conclusion: Freely available computer vision models could help annotate sedentary behaviour, typically the most prevalent activity of daily living, from wearable camera images within similar populations to seen data, reducing the annotation burden.

Yushuai Wu, Ting Zhang, Hao Zhou et al.

The fields of therapeutic application and drug research and development (R&D) both face substantial challenges, i.e., the therapeutic domain calls for more treatment alternatives, while numerous promising pre-clinical drugs have failed in clinical trials. One of the reasons is the inadequacy of Cross-drug Response Evaluation (CRE) during the late stages of drug R&D. Although in-silico CRE models bring a promising solution, existing methodologies are restricted to early stages of drug R&D, such as target and cell-line levels, offering limited improvement to clinical success rates. Herein, we introduce DeepCRE, a pioneering AI model designed to predict CRE effectively in the late stages of drug R&D. DeepCRE outperforms the existing best models by achieving an average performance improvement of 17.7% in patient-level CRE, and a 5-fold increase in indication-level CRE, facilitating more accurate personalized treatment predictions and better pharmaceutical value assessment for indications, respectively. Furthermore, DeepCRE has identified a set of six drug candidates that show significantly greater effectiveness than a comparator set of two approved drugs in 5/8 colorectal cancer organoids. This demonstrates the capability of DeepCRE to systematically uncover a spectrum of drug candidates with enhanced therapeutic effects, highlighting its potential to transform drug R&D.